COVID-19 vaccine induced interstitial lung disease

A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshifuji, Ayumi, Ishioka, Kota, Masuzawa, Yuya, Suda, Shuntaro, Murata, Saori, Uwamino, Yoshifumi, Fujino, Motoko, Miyahara, Hiromi, Hasegawa, Naoki, Ryuzaki, Munekazu, Hoshino, Haruhiko, Sekine, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450284/
https://www.ncbi.nlm.nih.gov/pubmed/34580010
http://dx.doi.org/10.1016/j.jiac.2021.09.010
Descripción
Sumario:A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

Ejemplares similares